Satsuma Pharmaceuticals to Present at the Cantor Virtual Global Healthcare Conference

Rhea-AI Summary

Satsuma Pharmaceuticals announced that CEO John Kollins will present at the Cantor Virtual Global Healthcare Conference on September 30, 2021, from 2:40 to 3:10 PM ET. The company is developing STS101, a nasal powder formulation of dihydroergotamine for migraine treatment, aiming to provide quick and convenient self-administration advantages over current treatments. Investors can participate through a webcast. A replay will be available for 90 days after the event.

SOUTH SAN FRANCISCO, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today announced that John Kollins, its President and Chief Executive Officer, is scheduled to present at the Cantor Virtual Global Healthcare Conference and invites investors to participate via webcast and in one-on-one meetings. Please see additional details below:

Cantor Virtual Global Healthcare Conference
	Date:	Thursday, September 30th
	Time:	2:40 to 3:10 p.m. ET
	Presenter:	John Kollins, President & CEO of Satsuma Pharmaceuticals
	Webcast:	Registration Link – Click Here
		* a replay will be available following the presentation for 90 days

Please contact your representative at Cantor Fitzgerald to schedule a virtual one-on-one meeting with Satsuma Pharmaceuticals during the respective conference.

For more information about the Cantor Virtual Global Healthcare Conference, please refer to the Cantor Fitzgerald conference website.

About Satsuma Pharmaceuticals and STS101

Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic product, STS101, for the acute treatment of migraine. STS101 is a unique and proprietary nasal powder formulation of the well-established anti-migraine drug, dihydroergotamine mesylate (DHE), administered via Satsuma’s proprietary 2^nd-generation nasal delivery device. STS101 is designed to provide significant benefits versus existing acute treatments for migraine, including the combination of quick and convenient self-administration and other clinical advantages, that current DHE liquid nasal spray products and injectable dosage forms lack. Satsuma’s dry powder DHE formulation has demonstrated fast absorption, rapid achievement of high DHE plasma concentrations which Satsuma believes is necessary for early efficacy, and sustained plasma levels over time with low dose to dose variability. Although DHE has long been recommended in published migraine treatment guidelines as a first-line acute treatment option for migraine and has significant advantages versus other anti-migraine treatments for many patients, disadvantages of current DHE liquid nasal spray and injectable products, including invasive and burdensome administration processes and/or sub-optimal clinical performance, have limited the widespread use of DHE. Featuring a compact and convenient dosage form, STS101 is designed to overcome these shortcomings and provide patients an improved therapeutic solution for acutely treating migraines that consistently delivers robust clinical performance.

Satsuma is headquartered in South San Francisco, California with operations in both California and Research Triangle Park, North Carolina. For further information, please visit www.satsumarx.com.

INVESTOR AND CORPORATE CONTACTS:  

Corey Davis, PhD
LifeSci Advisors, LLC
cdavis@lifesciadvisors.com

Tom O’Neil, Chief Financial Officer
Satsuma Pharmaceuticals, Inc.
tom@satsumarx.com

FAQ

What is the date and time of the Satsuma Pharmaceuticals presentation at the Cantor Virtual Global Healthcare Conference?

The presentation is scheduled for September 30, 2021, from 2:40 to 3:10 PM ET.

Who is the presenter for Satsuma Pharmaceuticals at the Cantor Virtual Global Healthcare Conference?

The presenter is John Kollins, President and CEO of Satsuma Pharmaceuticals.

What is STS101 and how is it related to migraine treatment?

STS101 is a novel nasal powder formulation of dihydroergotamine developed for the acute treatment of migraines.

How can investors access the webcast for Satsuma Pharmaceuticals' presentation?

Investors can access the webcast through the registration link provided on the Satsuma Pharmaceuticals website.

Is there a replay available for the Satsuma Pharmaceuticals conference presentation?

Yes, a replay will be available for 90 days following the presentation.